فهرست نشریات علمی دسترسی آزاد ایران

Background & aim: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age (15-44) years. Today, (50-80)% of patients with PCOS exhibit insulin resistance (IR) syndrome, which is worsened by hyperandrogenism-related adipose tissue accumulation. Metformin at a dose of (1700-2000) mg/day, with and without lifestyle is associated with a beneficial improvement on BMI and menstrual cycles. This study investigated the role of androgen profile, insulin resistance and adiponectin to evaluate the benefits of combined vitamin D and metformin in the treatment of PCOS.Methods: This cross-sectional study was included 50 infertile women who priory diagnosed with PCOS with age range (18-40 year). They were classified into; Group I:  Twenty-five women who were treated with metformin 850 mg/twice daily and followed for 8 weeks. Group II:  Twenty-five women who were treated with metformin 850 mg/twice daily plus vitamin D3 50.000 IU/wk., and followed for 8 weeks. Serum investigations included measurements of free testosterone, dihydrotestosterone, dehydroepiandrosterone-sulfate, sex-hormone binding globulin, HOMA-IR, 25-hydroxyvitamin D, and adiponectin, by ELISA technique.Results: This study revealed that the mean values of free testosterone (P<0.001), dihydrotestosterone (P<0.001) and waist circumference (P<0.021) were significantly improved (by lowering) after treatment with combined metformin plus vitamin D compared with metformin alone. Moreover, adiponectin mean value was significantly elevated after combined treatment in compared with metformin alone (P<0.001).Conclusion: Serum measurements of free testosterone, dihydrotestosterone and adiponectin are good indicators for efficacy of combined metformin plus vitamin D supplement in treatment of PCOS women.